The role of photovaporization of the prostate in small volume benign prostatic hyperplasia and review of the literature

被引:2
|
作者
Thomas, Dominique [1 ]
Zorn, Kevin C. [2 ]
Meskawi, Malek [2 ]
Goueli, Ramy [1 ]
Hueber, Pierre-Alain [2 ]
Deonarine, Lesa [1 ]
Misrai, Vincent [2 ]
Te, Alexis [1 ]
Chughtai, Bilal [1 ]
机构
[1] Weill Cornell Med Coll New York Presbyterian, Dept Urol, New York, NY USA
[2] Univ Montreal Hosp Ctr, Urol Sect, Dept Surg, Montreal, PQ, Canada
关键词
Benign prostatic hyperplasia; Photovaporization of the prostate; GreenLight XPS; Lower urinary tract symptoms; Small prostate; LASER PHOTOSELECTIVE VAPORIZATION; TRANSURETHRAL RESECTION; RANDOMIZED-TRIAL; SAFETY; EFFICACY; ENUCLEATION; MULTICENTER; INCISION; STANDARD; XPS;
D O I
10.1016/j.ajur.2019.01.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Our objective was to characterize the safety and efficacy of the 180 W XPS-GreenLight laser in men with lower urinary tract symptoms secondary to a small volume benign prostatic hyperplasia (BPH). Methods: A retrospective analysis was performed for all patients who underwent 180 W XPS-laser photoselective vaporization of the prostate (PVP) vaporization of the prostate between 2012 and 2016 at two-tertiary medical centers. Data collection included baseline comorbidities, disease-specific quality of life scores, maximum urinary flow rate (Q(max)), postvoid residual (PVR), complications, prostate volume and prostate-specific antigen (PSA). The secondary endpoints were the incidence of intraoperative and postoperative adverse events. Complications were stratified using the Clavien-Dindo grading system up to 90 days after surgery. Results: Mean age of men was 67.8 years old, with a mean body mass index of 29.7 kg/m(2). Mean prostate volume as measured by transrectal ultrasound was 29 mL. Anticoagulation use was 47% and urinary retention with catheter at time of surgery was 17%. Mean hospital stay and catheter time were 0.5 days. Median follow-up time was 6 months with the longest duration of follow-up being 22.5 months (interquartile range, 3-22.5 months). The International Prostate Symptom Score improved from 22.8 +/- 7.0 at baseline to 10.7 +/- 7.4 (p < 0.01) and 6.3 +/- 4.4 (p < 0.01) at 1 and 6 months, respectively. The Q(max) improved from 7.70 +/- 4.46 mL/s at baseline to 17.25 +/- 9.30 mL/s (p < 0.01) and 19.14 +/- 7.19 mL/s (p < 0.001) at 1 and 6 months, respectively, while the PVR improved from 216.0 +/- 271.0 mL preoperatively to 32.8 +/- 45.3 mL (p < 0.01) and 26.2 +/- 46.0 mL (p < 0.01) at 1 and 6 months, respectively. The PSA dropped from 1.97 +/- 1.76 ng/mL preoperatively to 0.71 +/- 0.61 ng/mL (p < 0.01) and 0.74 +/- 0.63 ng/mL at 1 and 6 months, respectively. No patient had a bladder neck contracture postoperatively and no capsular perforations were noted intraoperatively. Conclusion: The 180 W GreenLight XPS system is safe and effective for men with small volume BPH. PVP produced improvements in symptomatic and clinical parameters without any safety concern. It represents a safe surgical option in this under studied population. (C) 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.
引用
下载
收藏
页码:353 / 358
页数:6
相关论文
共 50 条
  • [1] Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia
    Sharib, Jeremy
    Truntzer, Jeremy
    Young, Jennifer
    Jordan, Gerald
    Gelman, Joel
    JOURNAL OF ENDOUROLOGY, 2012, 26 (05) : 520 - 523
  • [2] Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia Comment
    Elhilali, Mostafa
    JOURNAL OF ENDOUROLOGY, 2012, 26 (05) : 524 - 524
  • [3] Analysis of Predictive Factors of Success for Prostate Photovaporization in Benign Prostatic Hyperplasia by Greenlight Laser
    Miralles, J.
    Palmero, J. L.
    Ramirez-Backhaus, M.
    Osca, J. M.
    Benedicto, A.
    ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (01): : 20 - 24
  • [4] Photovaporization of benign prostatic hyperplasia with Greenlight Laser XPS™
    Fournier, G.
    PROGRES EN UROLOGIE, 2017, 27 (04): : F75 - F79
  • [5] The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review
    Vickman, Renee E.
    Franco, Omar E.
    Moline, Daniel C.
    Vander Griend, Donald J.
    Thumbikat, Praveen
    Hayward, Simon W.
    ASIAN JOURNAL OF UROLOGY, 2020, 7 (03) : 191 - 202
  • [6] Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review
    McNally, Christopher J.
    Ruddock, Mark W.
    Moore, Tara
    McKenna, Declan J.
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5225 - 5241
  • [7] Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature
    Cocci, Andrea
    Bocchino, Alessia Celeste
    Cito, Gianmartin
    De Lisa, Antonello
    Russo, Giorgio Ivan
    Lo Giudice, Arturo
    Sessa, Francesco
    Viola, Lorenzo
    Cindolo, Luca
    Somani, Bhaskar K.
    Siena, Giampaolo
    TURKISH JOURNAL OF UROLOGY, 2021, 47 (06): : 452 - 460
  • [8] Urodynamic evaluation of benign prostatic hyperplasia patients with urinary retention and small prostate volume
    Budaya, T. N.
    Daryanto, B.
    Hakim, L.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 123 - 123
  • [9] Association of receptor expression with prostate volume in benign prostatic hyperplasia
    Sreenivasulu, Karli
    Nandeesha, Hanumanthappa
    Dorairajn, Lalgudi N.
    Rajesh, Nachiappa G.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2019, 62 (01) : 99 - 102
  • [10] Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review
    Acar, Oguz
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2009, 8 (04): : 47 - 51